{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:33:15Z","timestamp":1791729195938,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2011,7,17]],"date-time":"2011-07-17T00:00:00Z","timestamp":1310860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Describe the centricity and histopathology profiles of each of the three classes of HIV-negative patients identified in this analysis.Correlate nosological classification and outcomes in patients with Castleman's disease.<\/jats:p>\n                  <jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Castleman's disease is a rare primary disease of the lymph nodes with limited available clinical information.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>A systematic literature search identified 416 cases amenable to detailed analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>In HIV\u2212 patients, centricity, pathology type, the presence of symptoms, gender, and age all predict outcome in univariate analyses. The 3-year disease-free survival (DFS) rate for patients with unicentric hyaline vascular disease (49.5% of cases, class I) was 92.5%, versus 45.7% for those with multicentric plasma cell disease (20.2% of cases, class III) and 78.0% for those with any other combination (22.6% of cases, class II) (p &amp;lt; .0001). HIV+ patients (class IV) exclusively presented with multicentric plasma cell disease and had a 3-year DFS rate of only 27.8%. Kaposi's sarcoma and lymphoma were observed in 59.3% and 9.4% of HIV+ patients and in 2.6% and 3.6% of HIV\u2212 patients (p &amp;lt; .0001). Paraneoplastic pemphigus and the syndrome of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes were observed exclusively in HIV\u2212 patients at a rate of 1.3% and 1.8%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Clinical, pathological, and viral markers allow for the classification of Castleman's disease into groups with markedly different outcomes and disease associations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0075","type":"journal-article","created":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T00:46:34Z","timestamp":1310949994000},"page":"1316-1324","source":"Crossref","is-referenced-by-count":143,"title":["Castleman's Disease: Systematic Analysis of 416 Patients from the Literature"],"prefix":"10.1093","volume":"16","author":[{"given":"Nadia","family":"Talat","sequence":"first","affiliation":[{"name":"Department of Endocrine Surgery, King's College Hospital, King's Health Partners, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Martin","family":"Schulte","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, King's College Hospital, King's Health Partners, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,7,17]]},"reference":[{"issue":"(10)","key":"2021122303521831500_B1","first-page":"396","article-title":"Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot","volume":"251","author":"Castleman","year":"1954","journal-title":"N Engl J Med"},{"key":"2021122303521831500_B2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4","article-title":"Localized mediastinal lymphnode hyperplasia resembling thymoma","volume":"9","author":"Castleman","year":"1956","journal-title":"Cancer"},{"key":"2021122303521831500_B3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ajh.21137","article-title":"HIV-associated multicentric Castleman's disease","volume":"83","author":"Stebbing","year":"2008","journal-title":"Am J Hematol"},{"key":"2021122303521831500_B4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrclinonc.2010.103","article-title":"Castleman's disease\u2014a two compartment model of HHV8 infection","volume":"7","author":"Schulte","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122303521831500_B5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/COH.0b013e328319bca9","article-title":"HIV-associated multicentric Castleman disease","volume":"4","author":"Oksenhendler","year":"2009","journal-title":"Curr Opin HIV AIDS"},{"key":"2021122303521831500_B6","first-page":"293","article-title":"Castleman disease","volume":"142","author":"Dispenzieri","year":"2008","journal-title":"Cancer Treat Res"},{"key":"2021122303521831500_B7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MOH.0b013e328186ffab","article-title":"Castleman disease","volume":"14","author":"Dham","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"2021122303521831500_B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05311.x","article-title":"The aetiology and management of Castleman disease at 50 years: Translating pathophysiology to patient care","volume":"129","author":"Casper","year":"2005","journal-title":"Br J Haematol"},{"key":"2021122303521831500_B9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/CMR.15.3.439-464.2002","article-title":"Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases","volume":"15","author":"Ablashi","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"2021122303521831500_B10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1473-3099(02)00288-8","article-title":"Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: Pathogenesis, Castleman's disease, and pleural effusion lymphoma","volume":"2","author":"Hengge","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"2021122303521831500_B11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#","article-title":"Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations","volume":"29","author":"Keller","year":"1972","journal-title":"Cancer"},{"key":"2021122303521831500_B12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/PAP.0b013e3181a9d4d3","article-title":"Castleman disease: An update on classification and the spectrum of associated lesions","volume":"16","author":"Cronin","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"2021122303521831500_B13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2006.09.019","article-title":"Castleman's disease: A rare lymphoproliferative disorder","volume":"18","author":"Jongsma","year":"2007","journal-title":"Eur J Intern Med"},{"key":"2021122303521831500_B14","first-page":"25","article-title":"Multicentric Castleman's disease in HIV infection: A systematic review of the literature","volume":"10","author":"Mylona","year":"2008","journal-title":"AIDS Rev"},{"key":"2021122303521831500_B15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1258\/095646206775220496","article-title":"Multicentric Castleman's disease in HIV infection","volume":"17","author":"Collins","year":"2006","journal-title":"Int J STD AIDS"},{"key":"2021122303521831500_B16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11864-005-0008-z","article-title":"Treatment of Castleman's disease","volume":"6","author":"Dispenzieri","year":"2005","journal-title":"Curr Treat Options Oncol"},{"key":"2021122303521831500_B17","first-page":"289","article-title":"The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma","volume":"312","author":"Casper","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"2021122303521831500_B18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/jmv.21349","article-title":"Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection","volume":"81","author":"Simonelli","year":"2009","journal-title":"J Med Virol"},{"key":"2021122303521831500_B19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002030-199601000-00009","article-title":"Multicentric Castleman's disease in HIV infection: A clinical and pathological study of 20 patients","volume":"10","author":"Oksenhendler","year":"1996","journal-title":"AIDS"},{"key":"2021122303521831500_B20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-005-0038-4","article-title":"Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease","volume":"85","author":"Casquero","year":"2006","journal-title":"Ann Hematol"},{"key":"2021122303521831500_B21","first-page":"61","article-title":"HIV-associated Castleman's disease: From case reports to evidence","volume":"12","author":"Bazeos","year":"2007","journal-title":"J HIV Ther"},{"key":"2021122303521831500_B22","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood-2007-08-106187","article-title":"Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease","volume":"110","author":"Powles","year":"2007","journal-title":"Blood"},{"key":"2021122303521831500_B23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000478-198803000-00002","article-title":"Multicentric angiofollicular lymph node hyperplasia. Pathology of the spleen","volume":"12","author":"Weisenburger","year":"1988","journal-title":"Am J Surg Pathol"},{"key":"2021122303521831500_B24","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s12032-009-9355-0","article-title":"A retrospective study of unicentric and multicentric Castleman's disease: A report of 52 patients","volume":"27","author":"Ye","year":"2010","journal-title":"Med Oncol"},{"key":"2021122303521831500_B25","article-title":"Surgery in Castleman's disease: Systematic review of 404 published cases","author":"Talat","journal-title":"Ann Surg"},{"key":"2021122303521831500_B26","first-page":"3","article-title":"Castleman's disease. A review","volume":"11","author":"Roca","year":"2009","journal-title":"AIDS Rev"},{"key":"2021122303521831500_B27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/asheducation-2004.1.283","article-title":"Atypical cellular disorders","author":"McClain","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122303521831500_B28","first-page":"150","volume-title":"Hematopathology","author":"Hsi","year":"2007"},{"key":"2021122303521831500_B29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.blre.2007.07.004","article-title":"POEMS syndrome","volume":"21","author":"Dispenzieri","year":"2007","journal-title":"Blood Rev"},{"key":"2021122303521831500_B30","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.96.8.4546","article-title":"Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma","volume":"96","author":"Dupin","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122303521831500_B31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-4632.2008.03444.x","article-title":"Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma without Castleman's disease; treatment with rituximab","volume":"47","author":"Meijs","year":"2008","journal-title":"Int J Dermatol"},{"key":"2021122303521831500_B32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1092-9134(99)80014-8","article-title":"Human herpesvirus-8 in lymphomatous and nonlymphomatous body cavity effusions developing in Kaposi's sarcoma and multicentric Castleman's disease","volume":"3","author":"Ascoli","year":"1999","journal-title":"Ann Diagn Pathol"},{"key":"2021122303521831500_B33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/1096-9896(200102)193:2<200::AID-PATH773>3.0.CO;2-L","article-title":"Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease","volume":"193","author":"Ascoli","year":"2001","journal-title":"J Pathol"},{"key":"2021122303521831500_B34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122303521831500_B35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.leu.2403709","article-title":"High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic\/plasmablastic diffuse large B-cell lymphoma","volume":"19","author":"Deloose","year":"2005","journal-title":"Leukemia"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/9\/1316\/41855263\/oncolo_16_9_1316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/9\/1316\/41855263\/oncolo_16_9_1316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T07:58:05Z","timestamp":1640246285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/9\/1316\/6400798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,17]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,7,17]]},"published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0075","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,9,1]]},"published":{"date-parts":[[2011,7,17]]}}}